To describe the relapse status of smokers aged ≥15 years in China, and investigate the main factors influencing their relapse behavior. The data of this study cames from the 2018 China Adult Tobacco Survey, covering 400 committees or villages in 200 districts or counties in 31 provinces (autonomous regions and municipalities) of China. The relevant data of smoking and relapsing in residents aged ≥15 years were collected by face-to-face interview. Software SAS 9.4 was used to clean and analyze the data, and logistic regression model was used to analyze the influencing factors for relapse rate. A total of 19 376 questionnaires were completed, with a response rate of 91.50%. In 2018, 66.05% of smokers aged ≥15 years in China had smoking relapse, in whom 66.59% were males and 55.79% were females. In all age groups, the age group 15-24 years had the highest smoking relapse rate (82.63%). Multivariate analysis showed that the younger age 15-24 years (=4.618,95%:1.981-10.763), e-cigarette use (=9.782,95%:3.139-30.490), and tobacco advertising, promotion and sponsorship in the past 30 days (=1.710,95%:1.291-2.265) were associated with higher smoking relapse rate. Compared with people who were allowed smoking at home or those without smoking limit, the smoking relapse rate in people who were not allowed to smoke at home (=0.562, 95%: 0.439-0.719) or those with smoking limit (=0.487, 95%: 0.366-0.647) was lower. The smoking relapse rate in Chinese smokers is high, especially in young people. It is suggested to conduct targeted intervention based on the results of this study to reduce the smoking relapse rate and help achieve the smoking control goal in Healthy China 2030.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3760/cma.j.cn112338-20211130-00929 | DOI Listing |
Objective: The ADVOCATE trial demonstrated that treatment of active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) with avacopan was noninferior in achieving remission at week 26 and superior for sustained remission at week 52 compared with a prednisone taper. This analysis of ADVOCATE evaluated the efficacy and safety of avacopan in patients with ear, nose, throat (ENT), or lung manifestations.
Methods: This post hoc analysis included patients enrolled in ADVOCATE with ENT or lung manifestations at baseline.
Lasers Surg Med
January 2025
Candela Institute for Excellence, Marlborough, Massachusetts, USA.
Background: The non-ablative 1940-nm laser induces controlled thermal damage at superficial depths without ablating the epidermis.
Objective: We evaluated a new 1940-nm fractional diode laser for improving pigmentation and skin texture.
Materials And Methods: Participants with mild to severe benign pigmented lesions received up to three laser treatments.
Stat Med
February 2025
Department of Statistics and Data Science, National University of Singapore, Singapore, Singapore.
The additive hazard model, which focuses on risk differences rather than risk ratios, has been widely applied in practice. In this paper, we consider an additive hazard model with varying coefficients to analyze recurrent events data. The model allows for both varying and constant coefficients.
View Article and Find Full Text PDFOrthop Surg
January 2025
Department of Spine Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People's Republic of China.
Objective: Unilateral biportal endoscopic discectomy (UBE) is an emerging and minimally invasive surgeryfor lumbar spinal degenerative disease. However, the efficacy, safety and the radiological changes of dural sac and paraspinal muscle of UBE compared with the conventional percutaneous transforaminal endoscopic discectomy (PTED) remains to be determined. The purpose of the study was to comprehensively compare the clinical efficacy between UBE and PTED in the surgical treatment of lumbar spinal degenerative disease.
View Article and Find Full Text PDFDiscov Oncol
January 2025
Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
B-cell non-Hodgkin lymphoma (B-NHL) is a highly heterogeneous group of lymphopoietic malignancies that account for 85% to 90% of all non-Hodgkin lymphomas. In recent years, CD19 Chimeric antigen receptor T (CAR T) cell immunotherapy has significantly improved the cure rate of B-NHL patients, but there are still some patients who cannot achieve remission after treatment, or relapse after remission. Therefore, it is of great importance to overcome the drug resistance of CD19 CAR T cells after B-NHL treatment and reduce the recurrence rate of CD19 CAR T cells after B-NHL treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!